ArticleCombinatorial chemistry & high throughput screening2026
Corrigendum to: FOLR1 Regulates the Malignant Progression of Glioblastoma through the SRC/ERK1/2 Axis.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum for
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been noted that in the published version of this article [1], the explanatory text for the "#" symbol was inadvertently omitted from the footnotes. The footnote has now been updated to properly reflect the equal contributions of the authors. Specifically, the following text has been added to the correspondence and affiliation section: "# These authors contributed equally to this work." The original article can be found online at https://www.benthamscience.com/article/145918 The publisher apologizes for any inconvenience caused.
Identifiers
42734236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.